Suvretta Capital Management

Zura Bio offers therapies for patients by incorporating immunology resources into phase 2 development programs, such as ZB-168 and torudokimab, with auto-immune illnesses. ZB-168 is an anti-IL7R inhibitor that may have an effect on disorders whose biological pathways are IL7 and TSLP. They create therapeutic indications for ZB-168 that build on the type 1 diabetes data from Phase 1b studies and show a profile and biological basis. The phase 2 clinical development stage of torudokimab, a human-affinity monoclonal antibody that neutralizes IL33, has been established.

ProKidney offers treatment of chronic kidney disease (CKD) through innovations in cellular therapy. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.

ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support. It connects the nursing community with opportunities and each other to build a supportive and thriving network.

Freenome is a biotech company developing accurate, accessible, and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. The company is developing a simple blood test to detect early-stage cancer and make treatments more effective and provides a platform that helps design healthy conditions for an individual based on his/her cell-free genome. The company aims to reinvent disease management through systematized early detection and intervention.

Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.

Alight Solutions provides cloud-based human capital solutions that empower clients and employees to manage health, wealth, and HR needs. Their platform combines data and analytics with a simple, seamless user experience.

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

Turntide specializes in developing sustainable technologies that drive down energy consumption and operating costs in buildings, agriculture, and electric transport, boosting bottom lines and accelerating a global path to 100% renewable energy. It has developed an efficient electric motor system, based on revolutionary switched reluctance technology, managed by advanced cloud software. Its goal is to eliminate the 25% of global electricity consumption that is wasted by legacy electric motors, thus accelerating the world’s transition from fossil fuels and leaving them in the ground where they belong. The company was founded in 2013 and is headquartered in Sunnyvale, California.

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.

Paysafe Group (Paysafe) is a specialized payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through industry-leading capabilities in payment processing, digital wallet, card issuing, and online cash solutions. Delivered through an integrated platform, Paysafe solutions are geared toward mobile-initiated transactions, real-time analytics, and the convergence between brick-and-mortar and online payments.

Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. The company's therapies leverage the natural repair process in several different nervous system cell types to target diseases such as multiple sclerosis, providing patients with a treatment to repair damage to the nervous system.

HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders. It creates human-relevant systems to accurately replicate the biology of organ systems and diseases for use throughout drug discovery and development. They work strategically in partnerships with pharmaceutical, biotechnology, and medical device companies. It generates meaningful human response data to increase confidence in decision-making, reduce the risk of costly failures, and identify efficacious therapies.

Gemini Therapeutics is a precision medicine company focused on genetically defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Their therapeutic candidates are matched to molecular abnormalities found in patients with high clinical needs and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, they are developing a series of potentially first-in-class therapeutics.

Terns Pharmaceuticals is a global biopharmaceutical company committed to discovering and developing molecularly-targeted, oral, small molecule drugs to treat liver disease and cancer. The company combines expertise in disease biology and medicinal chemistry with a capital-efficient drug discovery model and extensive clinical development capabilities in China to advance its growing pipeline of drugs that are optimized against clinically-validated targets. Based in San Mateo, California and Shanghai, Terns is focused on bringing forward innovative therapeutic candidates with the potential to address significant unmet medical needs in China and globally.

Solid Biosciences is to cure Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. DMD is a progressive, irreversible and ultimately fatal disease that affects approximately one in every 3,500 to 5,000 live male births and has an estimated prevalence of 10,000 to 15,000 cases in the United States alone. There is no cure for DMD and, for the vast majority of patients, there are no satisfactory symptomatic or disease-modifying treatments. Our lead product candidate, SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. Based on our preclinical program, we believe the mechanism of action of SGT-001 has the potential to slow or even halt the progression of DMD. In 2015, we began exclusively licensing the elements of the construct for SGT-001 and other elements of our gene transfer program from the University of Michigan, the University of Missouri and the University of Washington. SGT-001 has been granted Rare Pediatric Disease Designation in the US and Orphan Drug Designations in both the US and EU. Its safety and efficacy are currently being evaluated in a Phase I/II clinical trial.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

BioShin is a wholly owned subsidiary of Biohaven Pharmaceuticals, a public biotech company. BioShin is a clinical stage biopharmaceutical company focused on developing medicines. It has proven leadership from global industry and academic settings and a portfolio of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.

Molecular Partners is a clinical-stage biopharmaceutical company working to advance modern medicine and significantly improve the management of serious diseases. They are developing a powerful new class of potent, specific and versatile small protein therapies called DARPin® therapeutics.